logo

CELC

Celcuity·NASDAQ
--
--(--)
--
--(--)

CELC fundamentals

Celcuity (CELC) released its earnings on Mar 25, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.97 (YoY -14.12%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.97
-14.12%
Report date
Mar 25, 2026
CELC Earnings Call Summary for Q4,2025
  • FDA Priority Review: Gedatolisib NDA with PDUFA date July 17, 2026. Wild-type cohort shows 9.3-month PFS vs 2 months, hazard ratio 0.24.
  • Financial Health: $441.5M cash balance; Q4 net loss $51M, R&D up 11% to $37.6M.
  • Market Potential: $2.5B peak revenue in second-line breast cancer, $5B addressable market.
  • Clinical Momentum: Prostate cancer trial shows 9.1-month RPFS; mutant cohort results Q2 2026.
  • Strategic Readiness: Commercial infrastructure built, European submission planned Q4 2026.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Celcuity (CELC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Celcuity (CELC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Celcuity (CELC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Celcuity (CELC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Celcuity (CELC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Celcuity (CELC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield